Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2024: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Research at the Start |
In 2021 we established artificial intelligence (AI) methods to study the properties of the protein causing hemophilia A - a rare disease caused by defects in the FVIII protein and that impairs the blood coagulation. We observed a remarkable agreement between our results and hundreds of in vitro and clinical reports. Therefore, we are designing a novel FVIII-like protein that can be produced in non-mammalian cell lines and is invisible to the immune system. In all, we are creating the next generation of therapeutics and overcoming the two major burdens of actual hemophilia treatments.
|